NCI Funding for HIV and AIDS Malignancies Research

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Current NCI Funding Opportunities in HIV/AIDS and AIDS Malignancies are listed below.

HIV/AIDS and the Tumor Niche

The purpose of this RFA is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).

Additional Information:
HIV/AIDS and the Tumor Niche (R01)

Research on Non-AIDS-defining or AIDS-defining Cancers

The purpose of this initiative is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

Additional information:
"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01)
"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)

HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure Through Clinical Research

This initiative aims to fill scientific gaps needed to (a) inform HBV functional cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals.

Addittional Information:
HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R01)
HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R21)

In Vitro and Animal Model Studies on HBV/HIV Co-Infection

This initiative solicits application that will (a) stimulate and accelerate development of novel in vitro and small animal models of HBV/HIV co-infection to accelerate drug discovery/drug development in HBV/HIV co-infection; and (b) stimulate and accelerate a better understanding of the immunopathogenic interactions between HBV and HIV.

Additional Information:
In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01)
In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R21)

Multidisciplinary Studies of HIV/AIDS and Aging

The intent of this initiative is to solicit applications to study HIV infection, HIV-associated conditions including cancer, HIV treatment, and/or biobehavioral or social factors associated with HIV/AIDS in the context of aging and/or in older adults. Research approaches of interest include clinical translational, observational, and intervention studies in domestic and international settings.

Additional information:
Multidisciplinary Studies of HIV/AIDS and Aging (R03)
Multidisciplinary Studies of HIV/AIDS and Aging (R21)
Multidisciplinary Studies of HIV/AIDS and Aging (R01)

Harnessing Big Data to Halt HIV

This funding opportunity announcement (FOA) encourages applications that will transform understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). NIH is interested in promoting and applying Big Data Science technologies, computing, informatics, and analytics to address gaps in our understanding of HIV transmission risks, social networks, and the HIV treatment continuum including comorbidities such as cancer.

Additional information:
Harnessing Big Data to Halt HIV (R01)

  • Posted: May 4, 2017